3.9 Article

A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5

期刊

JOURNAL OF BIOMOLECULAR SCREENING
卷 21, 期 3, 页码 290-297

出版社

SAGE PUBLICATIONS INC
DOI: 10.1177/1087057115623264

关键词

epigenetics; RNA methyltransferase; RNA demethylase; METTL3; METTL14

资金

  1. AbbVie
  2. Bayer Pharma AG
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Eshelman Institute for Innovation
  6. Genome Canada
  7. Innovative Medicines Initiative (EU/EFPIA) [115766]
  8. Janssen
  9. Merck Co.
  10. Novartis Pharma AG
  11. Ontario Ministry of Economic Development and Innovation
  12. Pfizer
  13. Sao Paulo Research Foundation-FAPESP
  14. Takeda
  15. Wellcome Trust

向作者/读者索取更多资源

N-6-methyladenosine (m(6)A) is the most common reversible internal modification in mammalian RNA. Changes in m(6)A levels have been implicated in a variety of cellular processes, including nuclear RNA export, control of protein translation, and protein splicing, and they have been linked to obesity, cancer, and other human diseases. METTL3 and METTL14 are N-6-adenosine methyltransferases that work more efficiently in a stable METTL3-METTL14 heterodimer complex (METTL3-14). ALKBH5 is an m(6)A-RNA demethylase that belongs to the AlkB family of dioxygenases. We report the development of radioactivity-based assays for kinetic characterization of m(6)A-RNA modifications by METTL3-14 complex and ALKBH5 and provide optimal assay conditions suitable for screening for ligands in a 384-well format with Z factors of 0.78 and 0.77, respectively.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据